Autres langues Johnson & Johnson Kazakhstan S.E.

Actions

JNJ_KZ

US4781601046

Cours en clôture Kazakhstan S.E. Autres places de cotation 00:00:00 28/06/2024			Varia. 5j.	Varia. 1 janv.
149,6 ^USD	+1,39 %		-0,01 %	-4,98 %

01/07	Momentum Picks T3 2024 : 5 actions pour l'été
01/07	En Direct des Marchés : Thales, Airbus, Sanofi, Stellantis, Atos, Valneva, Boeing...

Autres langues

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Momentum Picks Q3 2024: 5 azioni per l'estate	01/07
CHMP adopts positive opinion for BALVERSA for the treatment of adult patients	01/07
Johnson & Johnson - Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class	01/07
New semester, new state of mind	01/07
Borsa di Italia: Un nuovo semestre, un nuovo umore	01/07
Bolsa de Madrid: Un nuevo semestre, un nuevo estado de ánimo	01/07
Johnson & Johnson : CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients	28/06
Johnson & Johnson Reports 'Positive' Results in Late-Stage Myasthenia Gravis Trial	28/06
J&J Unit's Rybrevant Combo Gets EU Approval	28/06
Nipocalimab pivotal Phase 3 trial demonstrates longest sustained disease control in FcRn class for broadest population of myasthenia gravis patients	28/06
Johnson & Johnson Announces Positive Results from the Nipocalimab Phase 3 Vivacity-MG3 Study	28/06
Johnson & Johnson : CHMP adopts positive opinion for BALVERSA® (erdafitinib) for the treatment of adult patients with unresectable or metastatic urothelial carcinoma with susceptible FGFR3 genetic alterations	28/06
Johnson & Johnson's Balversa Gets EU Panel Recommendation for Urothelial Carcinoma	28/06
Dealmakers optimistic on global M&A prospects despite sluggish growth	28/06
Lawyers for Johnson & Johnson’s Ovarian Cancer Victims React to SCOTUS Decision in Purdue	28/06
A New Wave Of ERISA Class Actions?: Some Employer/Fiduciary Implications Of Lewandowski V. Johnson & Johnson (Podcast)	27/06
US FDA declines to approve Merck-Daiichi's 'guided missile' cancer drug	27/06
Johnson & Johnson Reaches 50 Million Children Through Sight For Kids Program	25/06
US Supreme Court gives pharma companies a chance to thwart terrorism-funding lawsuit	24/06
J&J : 50M d'élèves aidés via le programme 'Sight for Kids'	24/06

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Joseph Wolk, CFO de J&J: Perte d'exclusivité de son médicament phare

Le 23 janvier 2024 à 18:30